This presentation by Professor Krzysztof Narkiewicz focuses on “moving” management of arterial hypertension, analysing 2018 ESC guidelines. The word “move” refers on how a faster blood pression (BP) control can be obtained through triple combination therapy that, according to clinical data, is considered more effective.
Another important topic is perindopril/amlodipine/indapamide single pill combination (SPC) use in hypertension management and cardiovascular events prevention.
An ideal SPC treatment should be:
- Useful in various clinical conditions and different age groups.
- Available in double and triple combinations with several drugs.
- Supported by EBM and suitable in providing protection.
In this context, perindopril/amlodipine/indapamide use is supported by the recent international guidelines and clinical trials because:
- Suitable second step in hypertension management.
- Facilitates BP control in difficult to manage hypertension.
- Consistent with patient’s expectation.
- Provides optimal CV protection.